Bridgebio Pharma, Inc. (BBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$74.84-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BBIO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | 713.1 | 502.1 | 221.9 | 9.3 | 77.6 | 69.7 | 8.2 | 40.6 |
| Cost of Revenues | 39.7 | 21.0 | 3.9 | 2.4 | 3.4 | 2.7 | — | — |
| Operating Expenses & Income | ||||||||
| Selling, General & Admin | 645.9 | 531.2 | 288.9 | 150.6 | 143.2 | 192.2 | 145.7 | — |
| R&D Expenses | 505.4 | 452.0 | 506.5 | 455.7 | 399.5 | 451.0 | 337.0 | 209.9 |
| Operating Income | (497.8) | (523.4) | (593.0) | (607.4) | (512.2) | (576.6) | (474.5) | (266.2) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | 53.1 | 99.3 | 81.3 | 80.4 | 46.8 | 36.7 | 8.8 |
| Interest & Investment Income | 23.5 | 19.9 | 17.2 | 18.0 | 7.5 | 1.1 | 4.0 | 8.9 |
| Net Interest Expenses | — | — | — | 63.3 | 72.9 | 45.6 | 32.6 | (0.2) |
| Other Non-Operating Income / Expenses | (205.9) | (209.1) | 50.8 | (45.9) | 27.6 | (9.8) | (31.0) | (22.3) |
| EBT, Incl. Unusual Items | — | (732.5) | (542.2) | (653.3) | (484.7) | — | 505.5 | 288.6 |
| Income Tax Expense | — | 0.4 | 1.2 | 0.0 | 0.0 | — | — | — |
| Net Income | ||||||||
| Minority Interest | (10.2) | (8.0) | (7.6) | (10.0) | (3.5) | (23.9) | (56.8) | (28.0) |
| Net Income | (702.0) | (732.9) | (543.3) | (653.3) | (484.6) | (586.5) | (505.5) | (288.6) |
| Per Share | ||||||||
| Basic EPS | (3.59) | (3.78) | (2.88) | (3.95) | (3.26) | (3.90) | (3.80) | — |
| Diluted EPS | (3.59) | (3.78) | (2.88) | (3.95) | (3.26) | (3.90) | (3.80) | — |
| Revenue per Share | 3.64 | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 195.8 | 191.5 | 186.1 | 162.8 | 147.5 | 144.4 | 118.0 | — |
| Diluted Weighted Avg Shares | 195.8 | 191.5 | 186.1 | 162.8 | 147.5 | 144.4 | 118.0 | — |
| Supplemental | ||||||||
| EBITDA | — | (518.0) | (586.9) | (603.3) | (508.1) | (573.3) | (473.0) | — |
| EBIT | (497.8) | (523.4) | (593.0) | (607.4) | (512.2) | (576.6) | (474.5) | (266.2) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.